Lantern Pharma Q2 net loss $4.5M; launches Phase 2 Harmonic trial for LP-300 in never-smoker NSCLC

Lantern Pharma Inc.

2023-Q2 EPS reported -$0.79

Net loss of $4.5M ($0.41 per share) vs $2.3M ($0.21) in Q2 2021; R&D spend increased to $3.0M from $1.2M.
Cash, cash equivalents, and marketable securities $62.2M as of June 30, 2022, down from $79.6M a year ago; cash runway into 2025.
Phase 2 Harmonic trial for LP-300 launched; enrollment begins Q3 2022; initial results expected Q4 2023.
INDs for LP-184 and LP-284 planned for early 2023; Phase 1 trials for LP-184 (CNS + solid tumors) and LP-284 (NHL) anticipated in H1 2023.
RADR platform now exceeds 21 billion data points; Dr. Maria Maccecchini elected to board of directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.